Creating New Businesses through Research and Development
First written in FY2021. 9 of 18 entries say "Restated". Latest entry: 2026-09-18.
38 other companies' latest entry also says "Advanced".
- 2026-09-18AdvancedManagement Planning
「We are conducting various demonstration projects in locations across Japan as part of efforts to promote community currencies rooted in local communities.」
コミュニティ通貨について、地域飲食店、子ども食堂・地域食堂、地域物産及びスポーツチーム等を対象とする実証実験の内容を具体化している。 - FY2026R&D site closureAnnual report
「June 2026: Closed the Sapporo R&D Center」
The Sapporo R&D Center was closed as an R&D site. However, R&D on applications for payment terminals, ASP performance improvements, and regional and community currencies is continuing. - FY2026-H1RestatedAnnual report
「R&D activities during the interim accounting period amounted to ¥32.148 million. During the interim accounting period, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥32.148 million. - FY2025R&D activities and expense updateAnnual report
「R&D expenses for the fiscal year amounted to ¥24.950 million for the Payment Integration business and ¥41.692 million in company-wide expenses not attributable to a specific segment. As R&D aimed at expanding existing businesses, we developed and tested applications for payment terminals scheduled for adoption and conducted development to improve the performance of existing payment terminals and ASP services.」
Continues R&D on payment terminal applications, terminal and ASP service performance improvements, and the commercialisation of regional and community currencies, and recorded total R&D expenses of ¥66.642 million. - FY2025-H1RestatedAnnual report
「R&D activities during the interim accounting period amounted to ¥35.859 million. During the interim accounting period, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥35.859 million. - FY2024SoftenedAnnual report
「Regarding the NUCADOCO business, we resolved on 14 August 2024 to discontinue the business.」
The company resolved to discontinue NUCADOCO, a health management support service that was one of the targets for creating new businesses through R&D. Meanwhile, R&D on regional and community currencies and related areas continues. - FY2024-Q3RestatedAnnual report
「R&D activities during the cumulative third quarter amounted to ¥16.197 million, comprising ¥6.212 million for the Payment Integration business and ¥9.984 million for other businesses. During the cumulative third quarter, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥16.197 million. - FY2024-Q2RestatedAnnual report
「R&D activities during the cumulative second quarter amounted to ¥13.410 million, comprising ¥5.982 million for the Payment Integration business and ¥7.427 million for other businesses. During the cumulative second quarter, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥13.410 million. - FY2023AdvancedAnnual report
「August 2022: Obtained a patent (Patent No. 7104951) for a healthcare system using the NUCADOCO (Note 6) avatar.」
In connection with creating new businesses through R&D, the company reports obtaining a patent for a healthcare system that forms the foundation of its health management support service as a milestone in its corporate history. It recorded R&D expenses of ¥159.322 million and continued R&D on payment terminal applications, ASP performance improvements, health management support services, and regional currencies. - FY2023-Q3RestatedAnnual report
「R&D activities during the cumulative third quarter amounted to ¥79.335 million. During the cumulative third quarter, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥79.335 million. - FY2023-Q1RestatedAnnual report
「R&D activities during the cumulative first quarter amounted to ¥17.329 million. During the cumulative first quarter, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥17.329 million. - FY2022AdvancedAnnual report
「July 2022: Renamed the Hokudai BS R&D Center as the Sapporo R&D Center and relocated it to Kita-ku, Sapporo, Hokkaido.」
Regarding its R&D sites, the company renamed and relocated the Hokudai BS R&D Center as the Sapporo R&D Center. It also continued R&D on payment terminal applications, ASP performance improvements, health management support services, and regional currencies, recording R&D expenses of ¥145.353 million for the fiscal year. - FY2022-Q3RestatedAnnual report
「R&D activities during the cumulative third quarter amounted to ¥109.421 million. During the cumulative third quarter, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥109.421 million. - FY2022-Q2RestatedAnnual report
「R&D activities during the cumulative second quarter amounted to ¥75.282 million. During the cumulative second quarter, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥75.282 million. - FY2022-Q1RestatedAnnual report
「R&D activities during the cumulative first quarter amounted to ¥40.083 million. During the cumulative first quarter, as in the previous fiscal year, we conducted R&D aimed at expanding existing businesses and at future commercialisation, with no material change in the status of our R&D activities.」
Continues R&D aimed at expanding existing businesses and future commercialisation, and recorded R&D expenses of ¥40.083 million. - FY2021First statedAnnual report
「We will focus on R&D and pursue the following 2 pillars: a. development to improve existing businesses and create new added value; b. research and development for demonstration projects through joint research with universities and research institutions.」
In addition to improving existing services, the company is researching the commercialisation of joint research with Hokkaido University and Senshu University, regional and community currencies, health management support services, and other businesses. R&D expenses are stated as ¥140.052 million.